Daratumumab: Beyond Multiple Myeloma

Kiran Ejaz; John D Roback; Sean R Stowell; Harold C Sullivan

doi:10.1016/j.tmrv.2021.06.002

Daratumumab: Beyond Multiple Myeloma

Transfus Med Rev. 2021 Jul;35(3):36-43. doi: 10.1016/j.tmrv.2021.06.002. Epub 2021 Jun 26.

Authors

Kiran Ejaz¹, John D Roback², Sean R Stowell², Harold C Sullivan³

Affiliations

¹ Department of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
² Department of Laboratory Medicine and Pathology, Emory University School of Medicine, Atlanta, GA, USA.
³ Department of Laboratory Medicine and Pathology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: hcsulli@emory.edu.

PMID: 34312046
DOI: 10.1016/j.tmrv.2021.06.002

Abstract

Daratumumab (DARA) is the biological name of an Immunoglobulin G1k human monoclonal antibody. DARA the first-in-class therapy targeting CD38 expressing- plasma cells (PC) and plasma blasts. It has been approved for the treatment of multiple myeloma. It is also being examined in the setting of other hematologic malignancies. As DARA targets PCs, it could potentially be used to treat many other disease processes that are antibody mediated. In fact, several case reports and case series report experiences of using DARA to treat a variety of antibody-mediated disorderss. The aim of this review is to present a summary of the literature thus far regarding the application of DARA beyond its uses in multiple myeloma and other hematologic diseases. Specifically, we address uses of DARA as an immunologic modulator in various antibody mediated processes.

Keywords: Antibodies; CD38 antigen (p45) protein; Monoclonal; plasma cells.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Multiple Myeloma* / drug therapy

Substances

Antibodies, Monoclonal
daratumumab